New cocktail aims to shrink sarcomas: bevacizumab joins chemo in phase 2 trial
NCT ID NCT07547592
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding the drug bevacizumab (Onbevzi) to standard chemotherapy (gemcitabine and docetaxel) can shrink tumors better than chemo alone in people with advanced soft tissue sarcoma. About 92 adults who have already had 1-2 prior chemotherapies will be randomly assigned to one of two groups. The main goal is to see how many patients' tumors shrink significantly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bevacizumab (Onbevzi), gemcitabine, docetaxel
What this could lead to
If adding bevacizumab works, this could give doctors a new, more effective drug combination for treating advanced soft tissue sarcoma.
What could go wrong
This is a mid-stage trial with only 92 people, so results may not apply to everyone. Adding bevacizumab also raises risks like bleeding and high blood pressure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEIOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••